Affiliate Assistant Professor
Department of Surgery, Cambridge University
Consultant Vascular Surgeon & Affiliate Assistant Professor
Cambridge University Hospitals NHS Trust
Cambridge, United Kingdom
Presenter
SESSION 8: MORE NEW DEVELOPMENTS REGARDING TBADS AND TEVAR: NEED FOR AND TIMING OF TEVAR FOR ACUTE UNCOMPLICATED TYPE B AORTIC DISSECTION (UTBADS) (FOR IMPORTANT RELATED TALKS SEE SESSION 8 IN OUR 2023 PROGRAM ON OUR WEBSITE VEITHSYMPOSIUM.ORG)
Presenter
SESSION 20: MORE HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT – EVALUATING ARTERIAL ANATOMY AND TREATMENT OUTCOMES WITH CLTI
Presenter
SESSION 41: OPEN AND ENDO TREATMENT OF COMPLEX AAAS (JUXTA, PARA- AND SUPRA-RENAL) AND TAAAS; INTERESTING NEW DEVICES FOR THEIR TREATMENT
SESSION 8: MORE NEW DEVELOPMENTS REGARDING TBADS AND TEVAR: NEED FOR AND TIMING OF TEVAR FOR ACUTE UNCOMPLICATED TYPE B AORTIC DISSECTION (UTBADS) (FOR IMPORTANT RELATED TALKS SEE SESSION 8 IN OUR 2023 PROGRAM ON OUR WEBSITE VEITHSYMPOSIUM.ORG)
TEVAR For Acute TBAD Significantly Reduces All-Cause Mortality At 3-Years Compared To Best Medical Management: New Data On Outcomes Of All Dissections In England: We Really Don't Need A Randomized Trial
5:14 PM - 5:19 PM
Presenter
SESSION 20: MORE HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT – EVALUATING ARTERIAL ANATOMY AND TREATMENT OUTCOMES WITH CLTI
How Should We Define Success For CLTI Treatment: What Criteria Are Best: The UK Perspective: Why Is It Different
2:40 PM - 2:45 PM
Presenter
SESSION 41: OPEN AND ENDO TREATMENT OF COMPLEX AAAS (JUXTA, PARA- AND SUPRA-RENAL) AND TAAAS; INTERESTING NEW DEVICES FOR THEIR TREATMENT
Secondary Interventions Up To 30 Days Following F/B/EVAR Of Complex AAAs: How Morbid Are They
9:58 AM - 10:03 AM